

DNA Methylation-Guided Prediction of Clinical Failure

PLoS ONE

10, e0130651

DOI: [10.1371/journal.pone.0130651](https://doi.org/10.1371/journal.pone.0130651)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A DNA Hypermethylation Profile Independently Predicts Biochemical Recurrence Following Radical Prostatectomy. <i>Urologia Internationalis</i> , 2016, 97, 16-25.	0.6	7
2	DNA Methylation and Urological Cancer, a Step Towards Personalized Medicine: Current and Future Prospects. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 531-549.	1.6	4
3	Distribution of polymorphic variants of the GSTP1 gene involved in biotransformation of xenobiotics in Tundra Nenets and Nganasans in comparison to Russians. <i>Human Physiology</i> , 2016, 42, 214-222.	0.1	1
4	Methylation in benign prostate and risk of disease progression in men subsequently diagnosed with prostate cancer. <i>International Journal of Cancer</i> , 2016, 138, 2884-2893.	2.3	12
5	Biomarkers in localized prostate cancer. <i>Future Oncology</i> , 2016, 12, 399-411.	1.1	39
6	The methylation status of GSTP1, APC, and RASSF1 genes in human prostate cancer samples: Comparative analysis of diagnostic informativeness of MS-HRM and hybridization on the Illumina Infinium HumanMethylation450 BeadChip. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2017, 11, 194-201.	0.2	3
7	DNA methylation and histone modifications as epigenetic regulation in prostate cancer. <i>Oncology Reports</i> , 2017, 38, 2587-2596.	1.2	86
8	The Genomic Impact of DNA CpG Methylation on Gene Expression; Relationships in Prostate Cancer. <i>Biomolecules</i> , 2017, 7, 15.	1.8	92
9	Epigenetic Signature: A New Player as Predictor of Clinically Significant Prostate Cancer (PCa) in Patients on Active Surveillance (AS). <i>International Journal of Molecular Sciences</i> , 2017, 18, 1146.	1.8	13
10	Hypermethylated DNA, a circulating biomarker for colorectal cancer detection. <i>PLoS ONE</i> , 2017, 12, e0180809.	1.1	62
11	The role of DNA methylation in ageing and cancer. <i>Proceedings of the Nutrition Society</i> , 2018, 77, 412-422.	0.4	147
12	Integrative (epi) Genomic Analysis to Predict Response to Androgen-Deprivation Therapy in Prostate Cancer. <i>EBioMedicine</i> , 2018, 31, 110-121.	2.7	15
13	The impact of DNA methylation on the cancer proteome. <i>PLoS Computational Biology</i> , 2019, 15, e1007245.	1.5	9
14	Random forest-based modelling to detect biomarkers for prostate cancer progression. <i>Clinical Epigenetics</i> , 2019, 11, 148.	1.8	89
15	Clinical protein science in translational medicine targeting malignant melanoma. <i>Cell Biology and Toxicology</i> , 2019, 35, 293-332.	2.4	33
16	Advances in Prognostic Methylation Biomarkers for Prostate Cancer. <i>Cancers</i> , 2020, 12, 2993.	1.7	16
17	Genomic data imputation with variational auto-encoders. <i>GigaScience</i> , 2020, 9, .	3.3	41
18	Benefits and pitfalls: Epigenetic modulators in prostate cancer intervention. <i>Current Research in Chemical Biology</i> , 2021, 1, 100006.	1.4	5

#	ARTICLE	IF	CITATIONS
19	Epigenetic biomarkers of disease. , 2021, , 117-141.		0
24	Challenges and Opportunities of Genomic Approaches in Therapeutics Development. Methods in Molecular Biology, 2021, 2194, 107-126.	0.4	2
25	Electrochemically detecting DNA methylation in the EN1 gene promoter: implications for understanding ageing and disease. Bioscience Reports, 2020, 40, .	1.1	5
26	Clinical and scientific considerations of genomics and metabolomics in radionuclide therapy. , 2022, , .		0
27	The Potential Role of Mitochondrial Acetaldehyde Dehydrogenase 2 in Urological Cancers From the Perspective of Ferroptosis and Cellular Senescence. Frontiers in Cell and Developmental Biology, 2022, 10, 850145.	1.8	2
28	EFFECTIVENESS OF EVALUATION OF APC, GSTP1 AND RASSF1A METHYLATION LEVEL AS A PROSTATE CANCER MARKER. Ulyanovsk Medico-biological Journal, 2022, , 73-85.	0.0	1
29	Epigenetic mechanism of therapeutic resistance and potential of epigenetic therapeutics in chemorefractory prostate cancer. International Review of Cell and Molecular Biology, 2023, , 173-210.	1.6	0
30	Genomic, epigenomic, and transcriptomic signatures of prostate cancer between African American and European American patients. Frontiers in Oncology, 0, 13, .	1.3	8